Cory Sago
Chief Executive Officer & Founder Amplitude Therapeutics
Cory Sago is co-founder & CEO of Amplitude Therapeutics, a seed-stage company developing differentiated RNA medicines and vaccines enabled by their trans-amplifying RNA platform. Previously, Cory co-founded and was CTO of Guide Therapeutics which advanced a novel, high-throughput platform to discover LNPs for RNA delivery variety of tissues including the liver, immune cells, and HSCs. GuideTx was acquired by Beam Therapeutics in 2021, where Cory served as Head of LNP Discovery. Cory received his PhD in Biomedical Engineering from Georgia Tech and Emory University.
Seminars
Thursday 28th May 2026
Unlocking Trans-Amplifying RNA to Deliver Self-Amplifying Potency with Improved Manufacturability & Dosing Control • Achieve robust levels of protein expression without over
11:30 am
- Achieve robust levels of protein expression without oversized RNA constructs by separating replicase and payload RNAs to improve delivery efficiency, formulation flexibility, and translation across species
- Increased drug substance flexibility to reduce CMC, scale-up, and regulatory risk versus traditional saRNA by simplifying RNA length, improving batch consistency, and enabling more predictable manufacturing
- Expand therapeutic applicability beyond vaccines by using trans-amplifying RNA to enable tunable expression, lower dosing, and modular payload design for protein replacement and in vivo biologic delivery
Thursday 28th May 2026
Panel: Contrasting Circular vs. Self-Amplifying RNA to Match Modalities to Use-Cases
9:00 am
- Weigh strengths and trade-offs in potency, durability, manufacturability, and safety to guide platform decisions
- Compare fit-for-purpose advantages across CAR-T, protein replacement, combination therapies, autoimmune, and CNS applications to reduce risk
- Define where each modality delivers a strategic edge and where constraints limit applicability for smarter portfolio planning
Thursday 28th May 2026
Harnessing Cascade Amplification & Therapeutic Payload (CATP) Systems to Unlock Potent, Low-Dose & Multi-Payload saRNA Therapeutics
11:00 am
- Achieve strong therapeutic expression at lower doses using a two-step amplification system that combines saRNA with defective viral replication to bypass current safety– efficacy limits
- Enable multi-gene and complex therapeutic logic through a dual-amplification system capable of supporting larger and more sophisticated payloads beyond traditional vaccine applications
- Improve targeting precision and reduce off-target liver accumulation with advanced delivery design that supports tissue- and cell-type–specific uptake for safer, more predictable translation
